A case study highlights a pediatric patient with Crohn's disease who developed primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder associated with vedolizumab. This finding underscores the need for vigilance regarding potential lymphoproliferative disorders in biologic-naïve patients.
vedolizumab associated primary cutaneous cd4 small medium t cell lymphoproliferative disorder in a biologic na ve pediatric patient with crohn s disease
Original title: “Vedolizumab-Associated Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorder in a Biologic-Naïve Pediatric Patient With Crohn's Disease.”